Clinical Trials Logo
  1. Home
  2. Myeloma Multiple
  3. NCT04436029
  4. Details
NCT04436029 Clinical Trial

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Myeloma Multiple Clinical Trial

Official title:
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04436029
Other study ID # DC 11B
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 12, 2020
Est. completion date March 10, 2022

Study information
Verified date March 2022
Source Cartesian Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.

Recruitment information / eligibility
Status Completed
Enrollment 4
Est. completion date March 10, 2022
Est. primary completion date March 10, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must be 18 years of age or older at the time of enrollment - High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs). Exclusion Criteria: - Patients who are pregnant or lactating. - Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Descartes 11
Car T-cells

Locations
Country Name City State
United States Center for Cancer and Blood Disorders Bethesda Maryland
United States Hackensack University Medical Center Hackensack New Jersey
United States Medical College of Wisconsin Madison Wisconsin
United States Stephenson Cancer Center Oklahoma University Health Science Centers Oklahoma City Oklahoma

Sponsors (1)
Lead Sponsor Collaborator
Cartesian Therapeutics

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Rate of stringent complete response 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06205823 - Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
Recruiting NCT04782687 - Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Phase 2
Active, not recruiting NCT05889221 - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma N/A
Recruiting NCT03891914 - Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma Phase 3
Not yet recruiting NCT05944783 - Bioequivalence Studies of Dasatinib 100 mg Phase 4
Recruiting NCT04268199 - A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment Phase 2
Not yet recruiting NCT06133426 - Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients N/A
Completed NCT05887206 - Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Completed NCT04065789 - Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients Phase 2
Active, not recruiting NCT03089411 - Collection of Additional Data Followed the Study IFM 2013-04 N/A
Not yet recruiting NCT04364724 - CTFEA Myeloma Study
Recruiting NCT05932680 - Limited-duration Teclistamab Phase 2
Not yet recruiting NCT06418750 - Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study N/A
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Terminated NCT04242121 - The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
Not yet recruiting NCT03607643 - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Phase 1/Phase 2
Recruiting NCT05651932 - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06245629 - Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Recruiting NCT03992170 - Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive Phase 2
Terminated NCT04843579 - Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients Phase 2